Drug Database
DI

diphtheria + pertussis + tetanus vaccine (Boostagen)

✓ Approved

BioNet-Asia Co.,Ltd. · Cell-based Therapies · Cell-based Therapies

What is diphtheria + pertussis + tetanus vaccine?

diphtheria + pertussis + tetanus vaccine is a cell-based therapies developed by BioNet-Asia Co.,Ltd.. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesBoostagen
CompanyBioNet-Asia Co.,Ltd.
Drug ClassCell-based Therapies, Vaccine
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, BioNet-Asia Co.,Ltd.

Therapeutic Indications

diphtheria + pertussis + tetanus vaccine is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedFrontiers in public health2026-07-25

Clinical characteristics and macrolide resistance analysis of pertussis in children: a retrospective study.

Zhang Huifen H, Yang Xiaoqing X, Guo Jiaowei J, Li Jiming J

Pertussis is mainly caused by Bordetella pertussis. Currently, no reports exist on the incidence of B. pertussis infection or on its patterns of macrolide resistance among pediatric cases in Xiamen, Fujian Province, China. The aim of this study was to determine the clinical characteristics and macrolide resistance patterns in pediatric pertussis. We retrospectively collected data from 968 children with pertussis between February 2021 and January 2025. Demographic characteristics, disease trends, clinical features, and macrolide resistance among outpatients and inpatients were analyzed. Most inpatients with pertussis were infants aged < 3 months, whereas most outpatients were school-aged children. Inpatients demonstrated significantly higher rates of leukocytosis, fever, co-infection, recent exposure to individuals with a cough, comorbid pneumonia, and macrolide use and experienced longer time from cough onset to confirmed diagnosis than did outpatients. The proportion of children who presented with spasmodic cough, violent coughing with facial flushing, inspiratory whoop, tachypnea, cyanosis, hypoxemia, and respiratory failure, as well as the average hospital stay, was significantly higher among children with severe pertussis than among those with common pertussis. Age younger than 3 months, being unvaccinated, co-infection, leukocytosis, lymphocytosis, spasmodic cough, facial flushing, inspiratory whoop, tachypnea, and cyanosis were risk factors for severe pertussis. Macrolides were the main antibiotics prescribed for children with pertussis. The detection rate of drug-resistant mutation sites was 77.52% in outpatients and 92.50% in inpatients. It is necessary to enhance the vaccination of pertussis for special populations, including women in the later pregnancy stages and school-aged children. Children with pertussis who have risk factors should be monitored to identify severe cases. The empirical use of macrolides for pertussis treatment is effective in most cases; alternative agents should be considered if the response is suboptimal, especially when drug-resistant mutation sites are identified.

PMID 42500007
Read full article →
PubMedAnnals of intensive care2026-07-25

A contemporary overview of severe community-acquired bacterial infections in pediatric intensive care units.

Levy Michael M, Mary Annelise A, Cour Andlauer Fleur F, Rousseaux Jeremie J et al.

Community-acquired bacterial infections (CABIs) remain a leading cause of pediatric morbidity and mortality. This study aimed to provide a contemporary description of pediatric CABIs requiring admission to pediatric intensive care units (PICUs) in France. The CAPRICE study is a prospective, multicenter cohort including all children with suspected CABIs who were admitted to 28 French PICUs from January to December 2024. Demographic, clinical, microbiologic, and outcome data were prospectively collected. The primary outcome was mortality at day 28 and secondary outcomes included sequelae at day 28, PICU length of stay, and total hospital stay. Independent predictors of mortality were identified by multivariable logistic regression. Among 897 children, the median age was 1.9 years (IQR 0.2-8.8); 55% were male, and 30% had a chronic condition. The leading infections were lower respiratory tract infection (43%), meningitis (20%), and ear-nose-throat infections (13%). Septic shock occurred in 17% of cases. A pathogen was identified in 89% of cases: Bordetella pertussis (22%) and Mycoplasma pneumoniae (15%) were predominant, followed by Streptococcus pneumoniae (13%), and Staphylococcus aureus (11%). In all, 34% patients had viral co-infection and 70% required organ support. Overall mortality was 7%, increasing to 19% with septic shock. Independent predictors of death included multiple organ failure, meningitis, and B. pertussis infection. Sequelae occurred in 15% of survivors. Severe CABIs in French PICUs in 2024 were mainly caused by B. pertussis and M. pneumoniae, followed by S. pneumoniae and S. aureus. Mortality and morbidity of these infections remain substantial.

PMID 42500454
Read full article →
PubMedJournal of the International AIDS Society2026-07-25

Behavioural and Structural Determinants of Mpox Vaccine Awareness and Uptake Among People With HIV in the Dominican Republic: A Cross-Sectional Study.

Paulino-Ramirez Robert R, Matias Wilfredo R WR, Chaumette Alexandre A, Lora-Rodríguez Hector H et al.

Mpox disproportionately affects people with HIV (PWH), yet little is known about mpox vaccine awareness and uptake in low- and middle-income countries. We evaluated mpox-related knowledge, attitudes and practices (KAP) among PWH in the Dominican Republic to identify determinants of vaccine awareness and uptake. We conducted a cross-sectional online survey of 98 PWH recruited through HIV clinics, community-based organizations and social networks (January-May 2025). The questionnaire assessed sociodemographic characteristics, mpox-related KAP, structural barriers and vaccination status. Univariable and multivariable logistic regression were used to examine factors associated with mpox vaccine awareness. Half of the participants (49/98) were aware of the mpox vaccine. Individuals aged 31-40 years had significantly lower odds of awareness compared with those aged 21-30 years. Despite high levels of formal education, 79% rated their mpox knowledge as low, and most perceived minimal personal risk. Among participants aware of the vaccine, 71% had been vaccinated. Structural barriers, including inconvenient site locations and logistical challenges, were frequently reported, even among vaccinated individuals, indicating that access limitations rather than hesitancy were the dominant constraints. Trust in vaccinating organizations was high overall, and healthcare providers and community organizations were the primary sources of vaccine information. Peer and community influence emerged as notable facilitators of uptake, while lack of reliable information and concerns about vaccine safety contributed to hesitancy. Mpox vaccine awareness among PWH in the Dominican Republic was low, but willingness to vaccinate was high when individuals were informed and able to access services. Strengthening mpox preparedness will require expanding accessible vaccination sites, improving disease-specific health literacy, and leveraging trusted community and clinical networks. Integrating mpox vaccination into routine HIV care delivery and enhancing community-led outreach may substantially improve uptake in this and similar low-middle income countries (LMIC) settings.

PMID 42499164
Read full article →
PubMedPneumonia (Nathan Qld.)2026-07-25

Pneumococcal pneumonia in adults - re-emergence of vaccine serotypes: a prospective multicenter cohort study in Germany, 2020-2023.

Bahrs Christina C, Rose Norman N, Barten-Neiner Grit G, Fleischmann-Struzek Carolin C et al.

The main burden of non-invasive pneumococcal diseases in adults is largely due to community-acquired pneumonia (CAP). This study aimed to investigate the distribution and dynamics of pneumococcal vaccine serotypes and to determine the proportion of CAP cases attributable to serotypes covered by 13-valent conjugate vaccine (PCV13), the 20-valent conjugate vaccine (PCV20), and the 23-valent polysaccharide vaccine (PPV23) among adults in Germany from 2020 to 2023. In this prospective multicenter cohort study, we analyzed all adult patients with CAP enrolled between January 1, 2020, and December 31, 2023, at 26 centers in Germany who provided urine samples for serotype-specific urine antigen detection (SSUAD) testing. Annual trends of pneumococcal vaccine serotypes from 2020 to 2023 were calculated for all patients and patient groups at risk using cluster-robust generalized linear models with heteroscedasticity-consistent standard errors. Of the 2,028 patients with all-cause CAP, 1,504 (1,008 patients aged ≥ 60 years, 373 younger patients with at least one comorbidity) had urine samples analyzed with SSUAD tests. Overall proportion of vaccine-type pneumococcal pneumonia among all-cause CAP for PCV13, PCV20, and PPV23 serotypes was 5.41% (95% CI 4.12-7.06%), 8.11% (95% CI 6.35-10.31%), and 8.31% (95% CI 6.27-10.93%), and serotype 3 was the most prevalent serotype (52 cases). Among patients aged ≥ 60 years, an increasing annual trend was observed for serotype 3 (OR 1.84, 95% CI 1.01-2.67), PCV13 (OR 1.89, 95% CI 0.89-2.89), PCV20 (OR 1.57, 95% CI 0.99-2.14), and PPV23 serotypes (OR 1.47, 1.04-1.91). The findings demonstrate that vaccine serotypes, particularly serotype 3, continued to circulate and reemerged among older adults with CAP in Germany.

PMID 42498972
Read full article →
PubMedHospital pharmacy2026-07-25

Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports.

Castellana Eleonora E, Chiappetta Maria Rachele MR

To describe the distribution and characteristics of adverse events following immunization (AEFI) using a large US pharmacovigilance database. A retrospective descriptive analysis of Individual Case Safety Reports (ICSRs) from the FDA AEMS database (January 2017-March 2026) was conducted. Reports were analyzed by vaccine type, adverse event terms, demographics, reporting year, and reporter category. A total of 2 169 603 ICSRs were identified, with 44.0% classified as serious. COVID-19 vaccines accounted for 78.4% of reports, reflecting mass vaccination campaigns. The most frequently reported events were headache (12.8%), pyrexia (11.8%), and fatigue (11.1%), predominantly non-serious and consistent with known reactogenicity profiles. Reporting peaked in 2021 (48.8%). Females accounted for 60.6% of reports. Non-COVID vaccines contributed substantially fewer reports. Most vaccine-associated adverse events were mild and expected. Findings support a favorable benefit-risk profile and highlight the importance of continuous pharmacovigilance systems for vaccine safety monitoring.

PMID 42500260
Read full article →
PubMedPediatric research2026-07-25

Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease.

Gadelha Carolina S E CSE, Terreri Maria Teresa MT, N Burian Ana Paula AP, da Fraga Aline C M ACM et al.

COVID-19 vaccines have significantly reduced mortality and are safe for healthy children; however, research in pediatric populations with juvenile immune-mediated inflammatory diseases (IMIDs) is limited. The Brazilian multicenter longitudinal SAFER-Study evaluates immunogenicity and safety of the BNT162b2/Pfizer vaccine in IMID patients. The juvenile cohort enrolled patients aged 12-17 years between August and December 2021 and compared them with adults under 40 years from the adult cohort. Safety was assessed by monitoring post-vaccination adverse events (AEs), immunogenicity was measured by IgG antibodies against the SARS-CoV-2 spike receptor-binding domain and seroconversion rates. A total of 123 participants were included: 86 adolescents and 37 adult controls. In adolescents, local AEs were most frequent; no serious or life-threatening AEs occurred. Significant increases in IgG-S levels were observed after the two doses in both cohorts (p < 0.001). Seroconversion after the second dose reached 97% overall and 100% after the third dose. In juvenile SLE and JIA patients, vaccination did not significantly affect disease activity. The BNT162b2 vaccine was safe and immunogenic in adolescents with IMIDs, including those with high immunosuppression and comorbidities, showing similar responses to adults. These findings support vaccination in this vulnerable population and contribute to evidence-based recommendations. BNT162b2 COVID-19 vaccine demonstrated a favorable safety profile and immunogenicity in adolescents with juvenile immune-mediated inflammatory diseases (IMID), with responses comparable to those observed in adults. Real life data on this population remain limited, and further evidence regarding vaccine safety and immunogenicity is needed. This study represents the first multicenter, longitudinal registry of Brazilian adolescents with IMID receiving BNT162b2. Comprehensive data on the safety and immunogenicity of BNT162b2 in highly immunosuppressed adolescents with IMID and comorbidities are crucial to guide clinical decision-making, mitigate vaccine hesitancy, and enhance vaccination coverage within this vulnerable population.

PMID 42498827
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria + pertussis + tetanus vaccine